Study of Nilotinib in Metastatic Melanoma With KIT Aberrations

NCT ID: NCT01099514

Last Updated: 2015-12-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 33 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-08-31
• Study Completion Date: 2015-06-30

Brief Summary

Major response was observed to imatinib mesylate in KIT-mutated metastatic rectal melanoma (Hodi FS et al, J Clin Oncol 26:2046-2051, 2008). In the ASCO annual meeting in 2009ar, KIT mutations were reported to be present in 23% of acral and 15.2% of mucosal melanomas (Heinrich MC et al, J Clin Oncol 26:2008 abstr 9016). Nilotinib is a novel tyrosine kinase inhibitor (TKI) targeting KIT, PDGFR, and Bcr-Abl and inhibiting the proliferating of both imatinib-sensitive and imatinib-resistant cells in vitro. Phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST) demonstrated significant activity (72% stable disease for nilotinib alone and 56% for nilotinib/imatinib combination) (Blay JY et al, J Clin Oncol 26:2008, abstr 10553).

Thus, we propose to conduct a phase II study of nilotinib in metastatic melanoma with KIT mutations.

Conditions

Metastatic Melanoma With KIT Aberration

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Nilotinib

Nilotinib 400 mg (2 capsules) PO BID q 28 days

Group Type: EXPERIMENTAL

Nilotinib

Intervention Type: DRUG

D1\~ Nilotinib 400 mg (2 capsules) PO BID q 28 days

Interventions

Nilotinib

D1\~ Nilotinib 400 mg (2 capsules) PO BID q 28 days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Histologically or cytologically proven melanoma with stage IV or unresectable stage III disease

2. Documented KIT aberration

3. Adequate organ function as defined by the following criteria:

• Serum aspartate transaminase (AST); serum glutamic oxaloacetic transaminase (SGOT)) and serum alanine transaminase (ALT); serum glutamic pyruvic transaminase (SGPT)) ≤ 2.5 x local laboratory upper limit of normal (ULN), or AST and ALT less than or equal to 5 x ULN if liver function abnormalities are due to underlying malignancy
• Total serum bilirubin ≤ 1.5 x ULN
• Absolute neutrophil count (ANC) ≥ 1500/µL
• Platelets ≥ 100,000/µL
• Hemoglobin ≥ 9.0 g/dL (may be transfused or erythropoietin treated)
• Serum calcium ≤ 12.0 mg/dL
• Serum creatinine ≤ 1.5 x ULN

4. Patients with CNS metastasis must have stable neurologic function without evidence of CNS progression within 8 weeks

5. May have previous adjuvant therapy with interferon, vaccines or therapy with IL-2, chemotherapy

6. At least one measurable lesion by RECIST criteria

7. ECOG PS 0-2

Exclusion Criteria

1. Major surgery or radiation therapy within 4 weeks of starting the study treatment.

2. History of or known carcinomatous meningitis, or evidence of symptomatic leptomeningeal disease on screening CT or MRI scan.

3. Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2.

4. QTc > 470 msec on baseline EKG.

5. Pregnancy or breastfeeding.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Samsung Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Jeeyun Lee

Samsung medical center

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Samsung Cancer Center

Seoul, , South Korea

Countries

South Korea

Other Identifiers

2009-02-026

Identifier Type: -

Identifier Source: org_study_id